

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00858)

**COMPLETION OF MAJOR TRANSACTION
IN RELATION TO
THE EXTENSION OF LOAN AGREEMENT
AND
PROVISION OF FINANCIAL ASSISTANCE**

Reference is made to the announcement dated 30 July 2024 and the circular dated 27 September 2024 (the “**Circular**”) of Extrawell Pharmaceutical Holdings Limited (the “**Company**”), and the poll results announcement of the special general meeting of the Company dated 15 October 2024. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

The Board announces that (i) all the conditions precedent to the First Loan Extension Agreement have been fulfilled on 15 October 2024 and the First Loan Extension shall take effect on 16 October 2024; and (ii) all the conditions precedent to the Third Shareholders’ Loan Agreement have been fulfilled on 15 October 2024 and the Third Shareholders’ Loan Agreement shall take effect on 16 October 2024 (“**Effective Date**”), and the drawdown(s) of the Facility can be made within twenty-four (24) months after the Effective Date.

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Chairman

Hong Kong, 15 October 2024

As at the date of this announcement, the executive directors are Dr. Xie Yi, Mr. Cheng Yong, Dr. Lou Yi, Ms. Wong Sau Kuen and Dr. Guo Yi, and the independent non-executive directors are Mr. Fang Lin Hu, Ms. Jin Song and Dr. Zeng Li.

* *For identification purpose only*